Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This study is comparing a new immune therapy approach (a T-cell engager drug called teclistamab) against a standard stem cell transplant to see which is better for newly diagnosed multiple myeloma patients who have responded well to initial treatment. **You may be eligible if...** - You are over 18 with newly diagnosed multiple myeloma - You are eligible for a stem cell transplant - You completed induction therapy (16–24 weeks) with a combination including a proteasome inhibitor, lenalidomide, and an anti-CD38 antibody, and achieved at least a partial response - Your disease was measurable at diagnosis - Your physical performance score is ECOG 0–1 **You may NOT be eligible if...** - You have significant organ dysfunction (kidneys, liver, heart, lungs) - You have active infections or other cancers - You are pregnant or breastfeeding - You have already received more than one line of treatment before this study Talk to your doctor to see if this trial is right for you.